Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAGON: Oral corticosteroid tapering in generalized myasthenia gravis treated with ravulizumab
jRCT2071260051Phase 4Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, open-label, single-arm trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoint: Primary endpoint: proportion of participants achieving corticosteroid discontinuation or major reduction without gMG deterioration. Started Jul 2026; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2071260051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260051.